Harrow, Inc. announced three new studies at the ASRS 2026 meeting supporting its retina products IHEEZO, a low-viscosity ocular anesthetic gel, and BYOOVIZ, an FDA-approved biosimilar to LUCENTIS. Early trial data suggest IHEEZO improves patient comfort and safety during eye injections, with further large-scale trial results expected by late 2026. Additionally, real-world data show no increased infection risk with IHEEZO, and Samsung Bioepis shared positive interim findings on BYOOVIZ's post-marketing safety. These findings reinforce Harrow's commitment to evidence-based retina care and long-term product adoption.
Tokenized U.S. Treasury bills are expanding across multiple blockchain platforms, with Solana adding $378.2 million in new issuance over 30 days, outpacing Ethereum's $272.2 million. Other blockchains like BNB Chain and zkSync Era also saw growth, wh...
Alnylam Pharmaceuticals lowered its full-year 2026 sales guidance by about $200 million due to slower growth after initial demand in the ATTR-CM market. This announcement led to a sharp drop in its stock price by more than 28%, causing significant lo...
Stripe is set to acquire OpenRouter, an AI gateway startup that offers access to multiple AI models, for more than $7 billion. OpenRouter, valued at $1.3 billion after a $113 million Series B funding round, provides users with a single platform to ch...
Avalanche (AVAX) price fell 2.39% to $6.34 as most altcoins weakened, making AVAX one of the poorest performers despite a flat overall crypto market. The decline lacks a specific catalyst and reflects broad market risk-off sentiment. However, whale a...
Austrian tax law treats swapping Bitcoin for stablecoins as a tax-neutral crypto-to-crypto transaction if the stablecoin qualifies as a cryptocurrency. This means the tax on Bitcoin gains is deferred, not canceled, with acquisition costs transferring...
